At a glance
Science Group is a science & technology business providing consultancy and systems to an international client base. The Group comprises five operating divisions, supported by a strong balance sheet including significant cash resources and freehold property assets. The Group provides products and services to clients in the key vertical markets of: medical, defence, food & beverage, industrial and consumer. With offices throughout Europe and North America, two dedicated R&D innovation centres, and employees fluent in over 30 languages, Science Group supports a global client base in over 100 countries.
Key investor information
Country and incorporation
Science Group plc is incorporated in the United Kingdom, with registered number 06536543. The main countries of operation are the UK and USA.
Other exchanges or trading platforms
The company is not listed on any other exchanges or trading platforms.
Restrictions on the transfer of securities
There are no restrictions on the transfer of securities.
UK city code on takeovers and mergers
Science Group plc is subject to UK City code on takeovers and mergers.
AIM rule 26
The information on this website is disclosed in accordance with AIM rule 26.
This page was last updated on 11 October 2023.
Securities in issue
The following information is correct as of 10 October 2023. Please check the latest Investor News for any subsequent changes.
The company's issued share capital comprises 46,185,874 ordinary shares, each with a nominal value of £0.01. Each share has equal voting rights. There are 45,976,506 ordinary shares in issue excluding treasury shares. The company holds 209,368 shares in treasury and a further 4,799 shares are held by the Frontier Smart Technologies Employee Benefit Trust. The total number of voting rights in the company is therefore 45,971,707.
The figure of 45,971,707 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the company, under the FCA's Disclosure and Transparency Rules.
So far as the company is aware, 39.23% of the issued share capital is not held in public hands. This includes the treasury shares held by the company and the shares held by the Frontier Smart Technologies Employee Benefit Trust.
The company has been notified of the following significant shareholders. Significant shareholders are those holding 3% or more of the voting rights in the company.
The Board reviews potential share buybacks on a regular basis. The Company does not normally announce when it will be, or will not be, undertaking buybacks. In addition, Investors should be aware that, from time to time, the Company will be in a closed period as required by the AIM Rules and other regulatory bodies, during which periods buybacks are not permitted. Closed periods are not announced by the Company but will include a period (minimum 30 days) prior to Interim and Preliminary Results announcements.
Board of directors
Martyn Ratcliffe was appointed Chairman on 15 April 2010 following his investment in Sagentia Group, now Science Group. He was Chairman of Microgen plc from 1998 to 2016 and Chairman of RM plc from 2011 to 2013. He was previously Senior Vice President of Dell Computer Corporation, responsible for EMEA. He has a degree in Physics from the University of Bath and an MBA from City University, London.
Group Managing Director
Dan Edwards was appointed to the Board on 24 April 2019. Mr Edwards joined the Company in 2004 and has held a number of roles within the Group including four years in the USA before being appointed Managing Director in 2012. He has an Engineering degree from the University of Cambridge and an MBA from Harvard Business School. He started his career at Rolls-Royce plc.
Jon Brett was appointed to the Board on 10 August 2021. Mr Brett joined Science Group as Group Financial Controller in March 2020, and was previously Group Financial Controller for Study Group Limited. He trained with Deloitte LLP and qualified as a Certified Accountant in 2004.
Senior Independent Director
Peter Bertram was appointed as a Non-executive Director on 17 June 2020. He was Chairman of Manolete Partners plc from 2018 until 2021 and has previously held a variety of other Non-Executive board positions including Low & Bonar plc, Alphameric plc, Anite plc, Microgen plc, Phoenix IT group plc and Psion plc. He was previously CEO of Azlan Group plc. Mr Bertram is a Chartered Accountant and has a degree in Accounting from the University of Kent.
Susan Clement Davies
Susan Clement Davies was appointed a Non-executive Director on 18 May 2022. Ms Clement Davies has over 25 years capital markets and investment banking experience, including 10 years at Citigroup/Salomon Smith Barney. She is currently Non-executive director of Evgen Pharma plc, Exploristics, MiNA Therapeutics and Scancell Holdings plc. She has an Economics degree from the University College London and an MSc in Economics from London School of Economics.
Nominated adviser & joint broker
Stifel Nicolaus Europe Limited
London EC2V 6ET
Liberum Capital Limited
25 Ropemaker Street
London EC2Y 9LY
Spencer Road, Lancing
Grant Thornton UK LLP
101 Cambridge Science Park,
The Board is committed to sound corporate governance and has adopted the Financial Reporting Council’s UK Corporate Governance Code July 2018 (“Code”). The Directors recognise the value of the Code and will take necessary measures to ensure that the Company complies taking into account the Company’s size and the nature of its business. This report sets out in broad terms how we comply at this point in time and where we are not compliant, sets out the reasoning.